Roche has struck a licensing and collaboration agreement with US-based Blueprint Medicines Corp for a drug entering registration for a group of cancers exhibiting mutations activated by the RET gene. The drug, pralsetinib, is being positioned to treat RET-altered non-small cell lung cancer, various types of thyroid cancer and other solid tumours.
